文献速递免疫规划传染病防控与疫情报告

住院退伍军人中Moderna与Pfizer-BioNTech COVID-19疫苗比较有效性及抗体应答——美国五个退伍军人事务医疗中心,2021年2月1日至9月30日

Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-12-10

在美国五个退伍军人事务医疗中心,对1896名退伍军人评估Moderna与Pfizer-BioNTech mRNA疫苗预防COVID-19相关住院的比较有效性,并比较234名完成接种且无感染证据者的血清抗体水平。调整后疫苗有效性在第二剂后14-119天Moderna为89.6%、Pfizer-BioNTech为86.0%,≥120天分别为86.1%和75.1%;Moderna接种者抗体水平在各年龄组和接种后时段均显著高于Pfizer-BioNTech接种者,但两种产品抗体水平均随时间下降。

要点

  • 第二剂后14-119天调整VE:Moderna 89.6%,Pfizer-BioNTech 86.0%。
  • 第二剂后≥120天调整VE:Moderna 86.1%,Pfizer-BioNTech 75.1%。
  • Moderna接种者抗体水平在各年龄组和接种后时段均显著高于Pfizer-BioNTech接种者。

核心结论

  • 来自老年、合并症高 prevalences 的住院退伍军人队列的发现提示,加强针对于帮助维持针对重症COVID-19的长期保护具有重要意义。

研究设计与样本

  • CDC与合作者在美国五个退伍军人事务医疗中心(VAMCs)于2021年2月1日至9月30日期间,对1896名美国退伍军人评估Moderna与Pfizer-BioNTech疫苗预防COVID-19相关住院的比较有效性,并比较234名完成mRNA疫苗接种且无当前或既往SARS-CoV-2感染证据者的血清抗体水平(抗刺突IgG和抗受体结合域IgG)。

主要发现

  • 第二剂Moderna后14-119天调整VE为89.6%(95% CI = 80.1%-94.5%),第二剂Pfizer-BioNTech后为86.0%(95% CI = 77.6%-91.3%)。
  • 第二剂后≥120天,Moderna的VE为86.1%(95% CI = 77.7%-91.3%),Pfizer-BioNTech为75.1%(95% CI = 64.6%-82.4%)。
  • Moderna接种者的抗体水平在各年龄组和接种后各时段均显著高于Pfizer-BioNTech接种者。
  • 两种产品接种者的抗体水平在14-119天至≥120天之间均下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.†.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Bajema KL, Dahl RM, Evener SL, et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34882654. doi:10.15585/mmwr.mm7049a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。